Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be severe and result in treatment termination. To date, no biomarker exists that can predict development of irAEs.We hypothesized that pre-treatment antibody profiles...